Loading…
Enovis Corporation is projected to rise to $35.73 by 2027, a +22% move from its current price of $29.30. ENOV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $28.26 | $29.31 | $30.41 | +0.04% |
| Aug 2 | $27.84 | $29.32 | $30.88 | +0.08% |
| Aug 3 | $27.53 | $29.33 | $31.26 | +0.12% |
| Aug 4 | $27.27 | $29.35 | $31.58 | +0.16% |
| Aug 5 | $27.05 | $29.36 | $31.86 | +0.20% |
| Aug 6 | $26.85 | $29.37 | $32.13 | +0.24% |
| Aug 7 | $26.67 | $29.38 | $32.37 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.67 | $29.38 | $32.37 | +0.28% |
| Week 2 | $25.69 | $29.46 | $33.79 | +0.55% |
| Week 3 | $24.98 | $29.54 | $34.94 | +0.83% |
| Week 4 | $24.40 | $29.62 | $35.96 | +1.11% |
| Week 5 | $23.92 | $29.71 | $36.89 | +1.39% |
| Week 6 | $23.49 | $29.79 | $37.77 | +1.67% |
| Week 7 | $23.11 | $29.87 | $38.60 | +1.95% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Enovis Corporation is a medical technology company that focuses on clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions.
The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients.
The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Enovis Corporation (ENOV) is a medical technology company currently trading at $30.26, with a market cap of $1.74B, and a market rank of 2150. The stock’s near-term outlook is reflected in the 2026 forecast, which shows an average price of $30.26 with 0 ROI and neutral sentiment.
Looking further out, the forecast shows a path of rising averages and positive ROI in multiple years, including a 2027 avg of $36.98 with 22.2% ROI and a bullish sentiment, continuing through 2030 with an average of $49.08 and 62.2% ROI. The long-range view extends to 2040 with an avg of $118.87 and 292.8% ROI, and to 2050 with an avg of $273.14 and 802.6% ROI, all with bullish sentiment.
A major floor 44.3% below — a decisive break under it would weaken the trend.
The nearest floor, 31.6% below — buyers have tended to step in here.
The nearest ceiling, 3.3% above — a clean break opens room to run.
A major ceiling 25.4% above — clearing it would confirm fresh momentum.
Key ENOV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENOV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.87 | Buy | $28.92 | Buy |
| MA 10 | $27.80 | Buy | $28.01 | Buy |
| MA 20 | $26.55 | Buy | $26.69 | Buy |
| MA 50 | $24.12 | Buy | $25.08 | Buy |
| MA 100 | $24.04 | Buy | $24.73 | Buy |
| MA 200 | $25.49 | Buy | $26.10 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.76 | Neutral |
| Stoch RSI (14) | 63.79 | Neutral |
| CCI (20) | 126.62 | Buy |
| Williams %R (14) | -17.11 | Info |
| MACD (12,26,9) | 0.32 | Buy |
| ROC (12) | 18.86 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 82.89 | Sell |
| TRIX (15) | 0.76 | Buy |
| Awesome (5,34) | 4.44 | Buy |
| Ultimate (7,14,28) | 65.81 | Neutral |
| Momentum (10) | 1.23 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 30.27 | Sell |
| ADX (14) | 18.92 | Neutral |
| ATR (14) | 0.97 | Info |
The 30-day technical picture is bullish on balance, with RSI14 at 70 and a sentiment label of BULLISH. The stock trades above its SMA measures, with SMA50 at $24.04 and SMA200 at $25.49, suggesting near-term positive momentum. The immediate resistance is positioned at $30.26 while support sits at $20.04.
The thirty-day price range spans from a low of $23.68 to a high of $38.67, indicating a broad trading channel in the near term. The stock’s annualized volatility is 70%, reflecting notable price movement potential within this period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $20.04 | $29.30 | $39.63 | 0% | Neutral | |
| $27.61 | $35.73 | $49.39 | +22% | Bullish | |
| $25.52 | $34.36 | $49.84 | +17% | Neutral | |
| $26.66 | $37.08 | $55.82 | +27% | Bullish | |
| $32.86 | $47.06 | $73.07 | +61% | Bullish | |
| $36.38 | $53.51 | $85.33 | +83% | Bullish | |
| $42.24 | $63.70 | $104.03 | +117% | Bullish | |
| $45.98 | $71.01 | $118.49 | +142% | Bullish | |
| $42.95 | $67.85 | $115.45 | +132% | Bullish | |
| $45.12 | $72.85 | $126.25 | +149% | Bullish | |
| $63.36 | $113.17 | $211.50 | +286% | Bullish | |
| $120.15 | $257.61 | $536.48 | +779% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $20.04 | $29.30 | $34.20 | +0.00% |
| August 2026 | $24.59 | $29.07 | $35.32 | -0.79% |
| September 2026 | $25.40 | $30.37 | $37.56 | +4.48% |
| October 2026 | $25.56 | $30.84 | $38.68 | +1.56% |
| November 2026 | $24.91 | $30.28 | $38.40 | -1.83% |
| December 2026 | $25.28 | $30.94 | $39.63 | +2.18% |
Click any year to see its month-by-month ENOV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ENOV to range from $20.04 to $39.63 through 2026. The $29.30 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ENOV price prediction for 2027 points to an average of $35.73 (low $27.61, high $49.39) — a potential gain of +22% on today's $29.30. Momentum favours further upside here.
In 2028, ENOV is projected to trade between $25.52 and $49.84, averaging $34.36 — a potential gain of +17% from today's $29.30. That is -4% versus the projected 2027 average. A consolidation phase looks the most probable path here.
Enovis Corporation's 2029 outlook centres on $37.08, within a $26.66 to $55.82 range. That is up +8% on the projected 2028 average. That marks a +27% change versus current levels. Momentum favours further upside here.
By 2030, ENOV could reach as high as $73.07, with a base case around $47.06 and support toward $32.86 — roughly +61% from $29.30. Buyers look set to stay in control over this stretch.
Expect ENOV to range from $36.38 to $85.33 through 2031. The $53.51 average target implies a +83% move from current prices. That is up +14% on the projected 2030 average. Momentum favours further upside here.
The ENOV price prediction for 2032 points to an average of $63.70 (low $42.24, high $104.03) — a potential gain of +117% on today's $29.30. Buyers look set to stay in control over this stretch.
In 2033, ENOV is projected to trade between $45.98 and $118.49, averaging $71.01 — a potential gain of +142% from today's $29.30. That is up +11% on the projected 2032 average. Momentum favours further upside here.
Enovis Corporation's 2034 outlook centres on $67.85, within a $42.95 to $115.45 range. That is -4% versus the projected 2033 average. That marks a +132% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ENOV could reach as high as $126.25, with a base case around $72.85 and support toward $45.12 — roughly +149% from $29.30. Momentum favours further upside here.
Expect ENOV to range from $63.36 to $211.50 through 2040. The $113.17 average target implies a +286% move from current prices. That is up +55% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ENOV price prediction for 2050 points to an average of $257.61 (low $120.15, high $536.48) — a potential gain of +779% on today's $29.30. Momentum favours further upside here.
Investing $1,000 in ENOV today (≈ 34.129693 ENOV) could be worth
$8,792.26
+$7,792.26 (+779%) by 2050 · US Dollar
Based on the average projected ENOV price of $257.61 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENOVwould be worth at today's price.
$1,000 invested in ENOV on Jul 30, 2025 (≈ 36.99593 ENOV) would be worth
$1,083.98
+$83.98 (+8.4%) today · 1.08× · US Dollar
Based on a ENOV entry price of $27.03 vs. today's $29.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $26.06 | $1,124.33 | +12.4% |
| 1 month ago | $20.7 | $1,415.46 | +41.5% |
| 3 months ago | $23.62 | $1,240.47 | +24.0% |
| 6 months ago | $22.04 | $1,329.4 | +32.9% |
| 1 year ago | $27.03 | $1,083.98 | +8.4% |
| All time (5.0y) ago | $78.92 | $371.28 | -62.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENOV forecast.
Our base-case forecast reaches $59.00 around 2032.
Implied market cap at $59.00: $3.4B
The multi-year forecast presents a bullish trajectory with substantial upside potential over the coming years. For 2030, the average forecast price is $49.08 with a 62.2% ROI, and sentiment remains bullish. By 2040, the average price is projected to $118.87 with a 292.8% ROI, continuing the bullish outlook.
In 2050, the average forecast rises to $273.14, supported by a very high 802.6% ROI and a bullish sentiment.
Earlier milestone years show a path of growth from 2027 (avg $36.98, ROI 22.2%, bullish) through 2029 (avg $38.54, ROI 27.4%, bullish), and into 2032 (avg $66.71, ROI 120.5%, bullish) and 2035 (avg $76.35, ROI 152.3%, bullish). These figures illustrate a long-run uptrend, with higher highs in the max forecasts (e.g., 2032 max $109.44, 2040 max $223.46, and 2050 max $572.70). These are estimates and not guarantees, and actual results may vary with market conditions.
Tap a question to reveal the answer.
Average forecast for 2030 is $49.08 with a min of $34.14, a max of $76.50, and ROI of 62.2%. Sentiment is BULLISH.
Forecasts show bullish sentiment in multiple years (e.g., 2027, 2029, 2030–2050) with positive ROI figures, but these are estimates and not guarantees.
Yes. The forecasted max for 2032 is $109.44, and higher max forecasts appear in later years (2040 max $223.46, 2050 max $572.70).
Current price is $30.26.
Average forecast for 2050 is $273.14, with a min of $125.69, a max of $572.70, ROI 802.6%, and sentiment BULLISH.
Enovis Corporation Community Discussion
0Share your Enovis Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.